Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

por Kadia, Tapan Mahendra, Kantarjian, Hagop M., Konopleva, Marina
Publicado 2019

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

por Wang, Xiaoning, Roy, Amit, Hochhaus, Andreas, Kantarjian, Hagop M, Chen, Tai-Tsang, Shah, Neil P
Publicado 2013

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia()()

por Delaunay, Jacques, Mazur, Grzegorz, Minden, Mark, Wierzbowska, Agnieszka, Jones, Mark M., Berrak, Erhan, Kantarjian, Hagop M.
Publicado 2013

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

por Chen, Joseph, Haughey, May, Vandendries, Erik, DeAngelo, Daniel J., Kantarjian, Hagop M., Ruiz‐Garcia, Ana
Publicado 2020

Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia

por Fares, Johny, Khalil, Melissa, Chaftari, Anne-Marie, Hachem, Ray, Jiang, Ying, Kantarjian, Hagop M, Raad, Issam I
Publicado 2019

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

por Kantarjian, Hagop M., Zugmaier, Gerhard, Brüggemann, Monika, Wood, Brent L., Horst, Heinz A., Zeng, Yi, Martinelli, Giovanni
Publicado 2021

Management of chronic myeloid leukemia in 2023 – common ground and common sense

por Senapati, Jayastu, Sasaki, Koji, Issa, Ghayas C., Lipton, Jeffrey H., Radich, Jerald P., Jabbour, Elias, Kantarjian, Hagop M.
Publicado 2023

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

por Kvasnicka, Hans Michael, Thiele, Jürgen, Bueso-Ramos, Carlos E., Sun, William, Cortes, Jorge, Kantarjian, Hagop M., Verstovsek, Srdan
Publicado 2018

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab

por Kantarjian, Hagop M., Logan, Aaron C., Zaman, Faraz, Gökbuget, Nicola, Bargou, Ralf C., Zeng, Yi, Zugmaier, Gerhard, Locatelli, Franco
Publicado 2023

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly dia...

por Mayer, Jiří, Arthur, Christopher, Delaunay, Jacques, Mazur, Grzegorz, Thomas, Xavier G, Wierzbowska, Agnieszka, Ravandi, Farhad, Berrak, Erhan, Jones, Mark, Li, Yuhan, Kantarjian, Hagop M
Publicado 2014

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

por Masarova, Lucia, Yin, C. Cameron, Cortes, Jorge E., Konopleva, Marina, Borthakur, Gautam, Newberry, Kate J., Kantarjian, Hagop M., Bueso-Ramos, Carlos E., Verstovsek, Srdan
Publicado 2017

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment

por Marks, David I., van Oostrum, Ilse, Mueller, Sabrina, Welch, Verna, Vandendries, Erik, Loberiza, Fausto R., Böhme, Sarah, Su, Yun, Stelljes, Matthias, Kantarjian, Hagop M.
Publicado 2019

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia...

por Rambaldi, Alessandro, Ribera, Josep‐Maria, Kantarjian, Hagop M., Dombret, Hervé, Ottmann, Oliver G., Stein, Anthony S., Tuglus, Catherine A., Zhao, Xiaoyue, Kim, Christopher, Martinelli, Giovanni
Publicado 2019

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

por Topp, Max S., Gökbuget, Nicola, Zugmaier, Gerhard, Stein, Anthony S., Dombret, Hervé, Chen, Yuqi, Ribera, Josep‐Maria, Bargou, Ralf C., Horst, Heinz‐August, Kantarjian, Hagop M.
Publicado 2020

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

por Hochhaus, Andreas, Baccarani, Michele, Giles, Francis J., le Coutre, Philipp D., Müller, Martin C., Reiter, Andreas, Santanastasio, Helene, Leung, Mimi, Novick, Steven, Kantarjian, Hagop M.
Publicado 2015

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or int...

por Kantarjian, Hagop M., Mamolo, Carla M., Gambacorti‐Passerini, Carlo, Cortes, Jorge E., Brümmendorf, Tim H., Su, Yun, Reisman, Arlene L., Shapiro, Mark, Lipton, Jeff H.
Publicado 2017

The importance of greater speed in drug development for advanced malignancies

por Stewart, David J., Stewart, Andrew A., Wheatley‐Price, Paul, Batist, Gerald, Kantarjian, Hagop M., Schiller, Joan, Clemons, Mark, Bradford, John‐Peter, Gillespie, Laurel, Kurzrock, Razelle
Publicado 2018

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia

por Ye, Dongjiu, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Xiao, Lianchun, Vadhan-Raj, Saroj, Fernandez, Michael H., Nguyen, Martin H., Medeiros, L. Jeffrey, Bueso-Ramos, Carlos E.
Publicado 2008

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

por Akard, Luke, Kantarjian, Hagop M., Nicolini, Franck E., Wetzler, Meir, Lipton, Jeffrey H., Baccarani, Michele, Khoury, H. Jean, Kurtin, Sandra, Li, Elizabeth, Munteanu, Mihaela, Cortes, Jorge
Publicado 2015

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

por Chung, Woonbok, Kelly, Andrew D., Kropf, Patricia, Fung, Henry, Jelinek, Jaroslav, Su, Xiang Yao, Roboz, Gail J., Kantarjian, Hagop M., Azab, Mohammad, Issa, Jean-Pierre J.
Publicado 2019